NCT07689864 Unified Network for Integrated Fluid Collection at Yale
| NCT ID | NCT07689864 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Molecular Residual Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2026-08-25 |
| Primary Completion | 2031-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2026-08-25 with a primary completion date of 2031-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
UNIFY is a Yale-wide liquid biopsy master repository that prospectively collects Streck-tube blood, dried blood spots (and optional archival tissue) from Yale Cancer Center patients across all tumor types for current and future research.
Eligibility Criteria
Inclusion Criteria: * Histological or radiological evidence of a suspected or confirmed solid tumor or hematologic malignancy, OR an individual identified as high-risk for cancer (based on identified germline aberration in a cancer predisposition gene, hormonal or medical risk factors, and/or significant family history of malignancy). * Willing and able to provide informed consent and HIPAA authorization for participation in UNIFY. * If being co-consented for a separate primary research study, the participant must also fulfill the eligibility criteria for that primary research study. Where there is a discrepancy in eligibility criteria between UNIFY and the primary research study, the primary research study's criteria take precedence. Exclusion Criteria: * Inability to provide informed consent. * Any medical contraindication to peripheral venipuncture as judged by the treating physician or research team (e.g., severe coagulopathy or other contraindication to additional research blood draw).
Contact & Investigator
Mitchell Elliott, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT07689864 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Molecular Residual Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07689864 currently recruiting?
Yes, NCT07689864 is actively recruiting participants. Contact the research team at Mitchell.elliott@yale.edu for enrollment information.
Where is the NCT07689864 trial being conducted?
This trial is being conducted at New Haven, United States.
Who is sponsoring the NCT07689864 clinical trial?
NCT07689864 is sponsored by Yale University. The principal investigator is Mitchell Elliott, MD at Yale University. The trial plans to enroll 2,500 participants.